The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Venetoclax combination therapies in AML
Andrew Wei, MBBS, PhD, of Alfred Hospital and Monash University, Melbourne, Australia, discusses viable options for combining venetoclax with targeted therapies in acute myeloid leukemia (AML). Specifically outlined is venetoclax combined with ivosidenib, an IDH1 inhibitor, as well as with gilteritinib, a FLT3 inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
